Press Releases
Dr. Gozani noted that the company has recorded orders for over 350 NC-stat® DPNCheck devices, the company's point-of-care test for the detection of systemic neuropathies such as diabetic peripheral neuropathy (DPN). DPN affects over 50% of people with diabetes and can lead to foot ulcers and amputation. He reiterated the company's goal which is to achieve the placement of 1,000 NC-stat DPNCheck devices by the end of 2012. Among the company's early customers is Wal-Mart Canada Corp. The NC-stat DPNCheck diagnostic test is performed with single-patient use biosensors. It is a "razor-razor blade" business model.
Dr. Gozani reviewed development progress for SENSUS, the company's second diabetes product which will extend the product line beyond diagnostics to therapeutics. SENSUS is intended to be used in the symptomatic relief and management of chronic intractable pain, such as painful diabetic neuropathy, a disabling complication of DPN. A premarket notification, or 510(k), was recently filed with the Food and Drug Administration (FDA). Subject to regulatory clearance, the company hopes to launch SENSUS by the end of 2012.
In an interview with CEOCFO http://ceocfointerviews.com/interviews/NURO-NeuroMetrix12.htm, Mr. Higgins reviewed 2012 milestones and also discussed those sectors of the overall diabetic peripheral neuropathy market which are most attractive to the company. Dr. Gozani and Mr. Higgins both pointed to near-term opportunities in retail medicine and managed care.
About NeuroMetrix
NeuroMetrix is a medical device company focused on the diagnosis and treatment of the neurological complications of diabetes. The Company currently markets products for the detection, diagnosis, and monitoring of diabetic neuropathies such as diabetic peripheral neuropathy and median neuropathy (carpal tunnel syndrome). For more information, please visit http://www.neurometrix.com.
SOURCE: NeuroMetrix
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief
Financial Officer
neurometrix.ir@neurometrix.com